Thr645

Site Information
LDDsDFEtEDFDVRs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 2907204
Available spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 )
Disease tissue studied:	breast cancer ( 2 , 3 , 15 , 17 ) , breast ductal carcinoma ( 3 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 ) , non-small cell lung cancer ( 6 , 7 , 8 , 10 , 11 , 12 , 13 , 14 , 16 ) , non-small cell lung adenocarcinoma ( 6 , 7 , 8 , 9 , 10 , 11 , 12 , 14 ) , non-small cell large cell lung carcinoma ( 7 , 10 ) , non-small cell squamous cell lung carcinoma ( 9 ) , small-cell lung cancer ( 5 )
Relevant cell line - cell type - tissue:	293 (epithelial) [ADRB1 (human), no information, overexpresses human beta1-adrenergic (ß1AR- HEK293)] ( 19 ) , A549 (pulmonary) ( 6 ) , breast ( 1 , 3 ) , BT-474 (breast cell) ( 2 ) , BT-549 (breast cell) ( 17 ) , Cal-12T (pulmonary) ( 12 ) , Calu-3 (pulmonary) ( 8 ) , DMS153 (pulmonary) ( 11 ) , DMS53 (pulmonary) ( 5 ) , HCC15 (pulmonary) ( 9 ) , HCC1937 (breast cell) ( 17 ) , HCC44 (pulmonary) ( 12 ) , HCC78 (pulmonary) ( 10 ) , HCC827 (pulmonary) ( 8 ) , HeLa (cervical) ( 18 , 19 ) , liver ( 4 , 20 ) , LOU-NH91 (squamous) ( 9 ) , lung ( 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 ) , MCF-7 (breast cell) ( 17 ) , MDA-MB-231 (breast cell) ( 17 ) , NCI-H1299 (pulmonary) ( 7 ) , NCI-H1355 (pulmonary) ( 6 ) , NCI-H1437 (pulmonary) ( 11 , 12 ) , NCI-H1650 (pulmonary) ( 8 ) , NCI-H1666 (pulmonary) ( 12 ) , NCI-H1703 (squamous) ( 9 ) , NCI-H1734 (pulmonary) ( 7 ) , NCI-H1781 (pulmonary) ( 10 ) , NCI-H1792 (pulmonary) ( 6 ) , NCI-H1944 (pulmonary) ( 7 ) , NCI-H1975 (pulmonary) ( 8 ) , NCI-H2073 (pulmonary) ( 9 , 11 ) , NCI-H209 (pulmonary) ( 11 ) , NCI-H2106 (pulmonary) ( 8 ) , NCI-H2228 (pulmonary) ( 10 , 14 ) , NCI-H23 (pulmonary) ( 6 ) , NCI-H2342 (pulmonary) ( 9 ) , NCI-H2405 (pulmonary) ( 12 ) , NCI-H3122 (pulmonary) ( 10 , 13 ) , NCI-H3255 (pulmonary) ( 16 ) , NCI-H358 (pulmonary) ( 7 ) , NCI-H441 (pulmonary) ( 6 ) , NCI-H446 (pulmonary) ( 5 ) , NCI-H460 (pulmonary) ( 7 ) , NCI-H526 (pulmonary) ( 5 ) , NCI-H661 (pulmonary) ( 10 ) , NCI-H69 (pulmonary) ( 5 ) , NCI-H82 (pulmonary) ( 5 ) , NCI-H838 (pulmonary) ( 11 ) , SKBr3 (breast cell) ( 15 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290 27362937 Curated Info
3	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
4	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
5	Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
6	Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
7	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
8	Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
9	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
10	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
11	Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
12	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
13	Rikova K (2013) CST Curation Set: 18860; Year: 2012; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT Curated Info
14	Rikova K (2013) CST Curation Set: 18859; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT Curated Info
15	Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57 22964224 Curated Info
16	Rikova K (2012) CST Curation Set: 16142; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC) Curated Info
17	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
18	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
19	Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50 18452278 Curated Info
20	Han G, et al. (2008) Large-scale phosphoproteome analysis of human liver tissue by enrichment and fractionation of phosphopeptides with strong anion exchange chromatography. Proteomics 8, 1346-61 18318008 Curated Info